Hemophilia without prophylaxis: Assessment of joint range of
Por um escritor misterioso
Descrição

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study - Matino - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library

PDF) Haemophilia and joint disease: pathophysiology, evaluation and management

Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A - Research and Practice in Thrombosis and Haemostasis

PDF] Guidelines for the management of haemophilia in Egypt

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet

Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age

Algorithm for management of emergency situations in patients with

Hemophilia Nursing Care Planning and Management Study Guide - Nurseslabs
Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers. - Document - Gale OneFile: Health and Medicine

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies - ScienceDirect

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B - ScienceDirect

Hematology Reports, Free Full-Text

COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA, International Journal of Technology Assessment in Health Care

Hemophilia Review

Hemophilia A Patients' Joint Health Improved by Eloctate, Study Shows
de
por adulto (o preço varia de acordo com o tamanho do grupo)